Urtė Fultinavičiūtė

Henlius has dosed the first patients across four biosimilar programs this summer, advancing daratumumab, nivolumab, cetuximab, and ipilimumab candidates in the US and China.

As generic semaglutide competition starts to line up, Novo Nordisk launches a cheaper copy of its GLP-1 blockbuster for diabetes.

Samsung Bioepis' Byooviz (ranibizumab-nuna) has relaunched in the US at an average sales price of $1,190 – nearly four times its previous level and higher than both the originator Lucentis and rival biosimilar Cimerli.

Celltrion is targeting more than its KRW5.3tr ($3.7bn) full-year guidance after H1 2026 revenues grew 45% year-on-year, driven by its newer slate of biosimilars that now accounts for the majority of biologics sales.

As artificial intelligence permeates its way into drug development, driving efficiency, speed, and profits, the environmental cost remains unaccounted.

Generics Bulletin senior reporter Urtė Fultinavičiūtė is joined by executive editor Dave Wallace for the inaugural episode of new interview podcast series “Off-Patent, On Record” to discuss how the generics and biosimilars industries have changed over the past decades.

As strong complex generic product performance and new launches drive its affordable medicines segment, Amneal has raised its annual revenue guidance for the second time in 2026.

The biosimilars community has celebrated several positive developments in both chambers of the US Congress.

Opuviz is now available in Europe in both vial and pre-filled syringe presentations, completing Samsung Bioepis' ophthalmology offering in the growing aflibercept market.

Amneal has completed its acquisition of Kashiv BioSciences, creating what it calls one of the industry's few fully integrated biosimilar platforms.